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Abstract  
Purpose: To determine whether oesophageal cancer survivors recover in health-related 
quality of life (HRQOL) within 10 years of surgery. 
Methods: A prospective, nationwide, population-based cohort study including 90% of all 
oesophageal cancer surgery patients in Sweden in 2001-2005, with follow-up through 2015. 
HRQOL was assessed 5 and 10 years postoperatively, using questionnaires for cancer in 
general (EORTC QLQ-C30) and oesophageal cancer specifically (EORTC QLQ-OES18). The 
HRQOL measures at 10 years after surgery were compared with the 5 year assessment. The 
10-year HRQOL scores were compared with a population-based reference population (4,910 
individuals), individually matched for age, sex, and comorbidity, by means of mean score 
differences with 95% confidence intervals.  
Results: Among 616 patients, 104 (17%) survived at least 10 years. Of these, 92 (88%) 
responded to the HRQOL questionnaires at 5 and 10 years after surgery. Among the 
responders, 71% were older than 70 years. Patients did not improve in HRQOL between 5 
and 10 years. Instead, the scores for 23 out of 25 HRQOL aspects declined, with clinically 
relevant and statistically significant deterioration in role function and appetite loss. 
Compared to the reference population, the 10 year survivors had worse scores in all 25 
HRQOL aspects, with significant deterioration in global quality of life, role functioning, social 
functioning, and most symptoms. The most severe problems compared to the reference 
population were reflux, eating difficulties, diarrhoea, and appetite loss.  
Conclusion: Patients who have undergone curative treatment for oesophageal cancer 
experience reduced HRQOL with persisting symptoms 10 years after surgery.   
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Background 
With an age-adjusted incidence rate of 4.3 per 100,000 persons,1 oesophageal cancer is the 
8th most common cancer globally.2 The prognosis is poor (<20% 5-year survival) because of 
late symptom presentation and early metastatic spread.2,3 The dominant curatively intended 
treatment involves surgical resection, often in combination with neoadjuvant chemotherapy 
or chemoradiotherapy.4 The surgery is extraordinarily extensive and entails >40% risk of 
postoperative complications5,6 and a 5-year survival of 40% for patients without metastatic 
spread.1 The postoperative recovery is typically slow with long-lasting impairments in health-
related quality of life (HRQOL).7,8 HRQOL is greatly affected immediately after surgery, and 
although some patients regain their preoperative HRQOL within the first year of surgery,9 
several symptoms may persist.10,11 Importantly, a significant subgroup of patients experience 
worsening of HRQOL still 5 years after surgery for oesophageal cancer.12,13 Oesophageal 
cancer survivors usually no longer receive follow-up healthcare after 3 to 5 years of surgery. 
Yet, the pattern of longer-term recovery (beyond 5 years of surgery) in HRQOL is not known. 
It is, however, of great importance for patients, healthcare, and society to know the 
expected long-term recovery. Such knowledge could help the planning of the long-term 
needs of these patients. The aim of this study was to determine the HRQOL in 10 year-
survivors of oesophageal cancer surgery.  
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Methods 
Design 
This prospective and population-based cohort study included 90% of all oesophageal cancer 
surgery patients in Sweden between April 1, 2001 and December 31, 2005. For the purpose 
of this study, patients were followed up for 10 years, and HRQOL data were obtained at 5 
and 10 years following surgery. Patients’ HRQOL measures at 10 years were compared with 
their HRQOL measures at 5 years, as well as the HRQOL measures of a reference population. 
Informed consent was obtained from all participants. The Regional Ethical Review Board in 
Stockholm, Sweden approved the study.  
 
Data collection 
A detailed description of this nationwide data collection can be found in other 
publications.5,14 In brief, the study was based on a complete, nationwide network of 174 
Swedish hospital departments with contact clinicians involved in diagnostic procedures or 
treatment of patients with oesophageal cancer. Information regarding patient and tumour 
characteristics, treatment, and complications were prospectively collected, and based on a 
predefined study protocol to ensure completeness and uniformity. Comorbidity was 
predefined as diabetes; cardiac, respiratory, renal or other specified conditions. By linking 
the unique personal identity number, assigned to all residents in Sweden, information about 
comorbidity was collected from the Swedish Patient Register, which contains all in-hospital 
diagnoses in Sweden since 1987 and all out-patient specialist care since 2001. Patients’ self-
reported HRQOL was collected by validated questionnaires at 6 months, 3, 5, and 10 years 
after surgery for oesophageal cancer. The cohort has been used for publications examining 
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HRQOL up to 5 years following surgery.12,15,16 This is the first study using the cohort to 
examine HRQOL 10 years after surgery. 
 
Health-related quality of life assessment  
HRQOL was assessed using two self-administered questionnaires, both developed and 
validated by the European Organisation for Research and Treatment of Cancer Quality of Life 
(EORTC).17,18 The EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) consists of 30 items 
for measuring HRQOL aspects in cancer patients in general.17 Questionnaire items are 
grouped into one global quality of life scale, five function scales (physical, role, emotional, 
cognitive, and social), three symptom scales (fatigue, nausea/vomiting, and pain), and six 
single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial 
difficulties). An oesophageal cancer-specific questionnaire, the EORTC Quality of Life 
Questionnaire–OES18 (QLQ-OES18) was used to assess problems common among 
oesophageal cancer patients.18 This 18-item questionnaire consists of four scales (dysphagia, 
reflux, eating difficulties, and oesophageal pain), and six single items (trouble swallowing 
saliva, choking, dry mouth, coughing, speech difficulties, and tasting problems). In both 
questionnaires, the four response alternatives were: “not at all”, “a little”, “quite a bit”, and 
“very much”. The only exception was the global quality of life scale, which had a seven-
graded rating, ranging from 1 (“very poor”) to 7 (“excellent”). 
  
Reference population 
To obtain normative data for the QLQ-C30 and QLQ-OES18 questionnaires, a random sample 
of 6,969 adults in Sweden was invited to participate.19 Among 4,910 (70.5%) participants, 
complete HRQOL data were obtained from 4,867 (99.1%) individuals. These data were used 
    
 
6 
 
as a proxy for baseline HRQOL, i.e., before the presentation of the cancer. Each patient in 
the operated cohort was individually matched by age (at HRQOL assessment), sex, and 
comorbidity (diabetes; cardiac, respiratory, renal or other specified conditions) to the 
reference population. This resulted in approximately 90 matched individuals (controls) from 
the reference population to each patient. This matching was done separately for the 5-year 
and 10-year assessment to avoid influence of older age and more comorbidity. Information 
about comorbidity was self-reported by the participants.  
 
Statistical analysis 
Questionnaire responses were linearly transformed into scores between 0-100, according to 
the scoring procedure in the EORTC manual.20 In the global quality of life scale and the 
function scales, higher scores represent better HRQOL, whereas higher scores in symptom 
scales and individual items correspond to more symptoms. Missing items were handled as 
recommended in the EORTC scoring manual.20 HRQOL measures were presented as mean 
scores with 95% confidence intervals (CIs).  A difference of ≥10 mean scores between 5 and 
10 years after surgery and between patients assessed at 10 years postoperatively and the 
reference population was defined as clinically relevant, since such mean score difference 
represents an appreciable difference in patients.21 Therefore, statistical significance was only 
calculated for clinically relevant changes. Linear regression models were used to estimate 
mean score differences with 95% CIs between patients’ HRQOL at 10 years after surgery and 
the reference population.  
 
To investigate the extent of individual HRQOL changes between 5 and 10 years, compared to 
the reference population, we further categorized data into three groups: “improved”, 
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“stable”, or “deteriorated” for each HRQOL aspect. Thus, patients could be categorized as 
“deteriorated” in one function, but “improved” in a symptom, for example. “Improved” was 
defined as an increase of ≥10 mean scores in global quality of life and function scales, or a 
decrease of ≥10 mean scores in symptoms. “Deteriorated” represented a reduction of ≥10 
mean scores in global quality of life or function scales, or an increase of ≥10 mean scores in 
symptoms. “Stable” defined a <10 mean score change between 5 and 10 years after surgery.  
 
Statistical significance was analysed when the mean score differences were ≥10. Paired t-
test was used for comparing mean scores at 5 years and 10 years and for comparison 
between patients who were categorized as improved, stable and deteriorated over time. 
Linear regression models were used when comparing patients’ HRQOL at 10 years with the 
reference population’s scores. P-values <0.01 were considered statistically significant.  
The statistical software SAS 9.4 (SAS institute Inc., Cary, NC) was used for all statistical 
analyses, while STATA 12 for Windows (STATA Corp, College Station, TX, USA) was used for 
producing graphs.   
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Results 
Patients 
Among 616 patients included in the original cohort, 104 (17%) survived for at least 10 years. 
Among these, 92 (88%) responded to the HRQOL questionnaires at the 5 and 10 year follow-
ups and were included in this study. Characteristics of included patients are presented in 
Table 1. Most patients were men, 71% were older than 70 years, and half hade one or more 
comorbidity .The dominating tumour type was adenocarcinoma of early pathological stage. 
A majority of patients underwent transthoracic surgery, 5% received neoadjuvant therapy 
and a third had postoperative complications.  
 
HRQOL at 10 years compared to the reference population 
Ten years after oesophageal cancer surgery, patients reported worse HRQOL scores in all 25 
aspects compared to the reference population (Table 2, Figure 1 and 2). The mean score 
differences were clinically relevant and statistically significant for global quality of life, role 
function, social function, fatigue, nausea/vomiting, dyspnoea, insomnia, appetite loss, 
diarrhoea, dysphagia, reflux, eating difficulties, oesophageal pain, trouble swallowing saliva, 
choking, dry mouth, coughing, and taste problems. The most outstanding problems 
compared to the reference population were reflux (mean score difference: 34, 95% CI: 28 to 
40; p<0.0001), eating difficulties (mean score difference: 27, 95% CI: 21 to 32; p<0.0001), 
diarrhoea (mean score difference: 24, 95% CI: 18 to 30; p<0.0001), and appetite loss (mean 
score difference: 22, 95% CI: 15 to 29; p<0.0001). 
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HRQOL changes between 5 and 10 years 
On group level, there were no statistically or clinically relevant improvements in HRQOL 
between 5 and 10 years of surgery. Instead, the scores for 23 out of 25 aspects declined, 
while the scores representing financial difficulties and dysphagia remained the same (Table 
2). Most of these mean score differences were not clinically relevant, but clinically relevant 
and statistically significant deteriorations were found for role function (mean score 
difference: -10, 95% CI: -16 to -5; p=0.0005) and appetite loss (mean score difference: -10, 
95% CI: 4 to 16: p=0.0007).  
 
HRQOL in patients who improved, were stable, and deteriorated between 5 and 10 years 
of surgery compared to HRQOL of the reference population 
Improved: Even though no improvements in HRQOL could be seen on group level, 23-80% of 
patients improved between 5 and 10 years of surgery with HRQOL scores equivalent to what 
was reported by the reference population (Table 3). Reflux was the only aspect that became 
worse than the reference population both clinically and statistically significantly (mean score 
difference: 17, 95% CI: 8 to 26; p=0.0007).  
Stable: In 7- 51% of patients who were stable in HRQOL between 5 and 10 years of surgery 
had clinically relevantly and statistically significantly worse scores than the reference 
population in all 25 HRQOL aspects (Table 3). The differences were particularly strong (>30 
mean score difference) for role function (in 10% of patients), social function (11%), appetite 
loss (11%), constipation (8%), diarrhoea (22%), financial difficulties (7%), reflux (24%), 
trouble swallowing saliva (10%), choking (22%), speech difficulties (7%), and taste problems 
(10%)(Table 3). 
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Deteriorated: Among 12-47% of patients who deteriorated in HRQOL between 5 and 10 
years of surgery had clinically relevantly and statistically significantly worse scores than the 
reference population in all 25 HRQOL aspects, and all mean score differences were >20 
(Table 3). The most outstanding mean score differences (>40) were found for role function 
(in 38% of patients), nausea/vomiting (28%), dyspnoea (34%), insomnia (25%), appetite loss 
(32%), constipation (15%), diarrhoea (27%), financial difficulties (12%), reflux (39%), eating 
difficulties (35%), trouble swallowing saliva (16%), choking (18%), dry mouth (28%), coughing 
(29%), speech difficulties (14%), and taste problems (16%)(Table 3).   
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Discussion 
This study shows that patients who have undergone surgery for oesophageal cancer 10 years 
earlier continue to deteriorate in HRQOL rather than recover. Their HRQOL is substantially 
worse that the reference population, with the most outstanding symptoms being reflux, 
eating difficulties, diarrhoea, and appetite loss. 
 
Some methodological issues warrant consideration. A limitation is the lack of preoperative 
baseline HRQOL data. However, obtaining HRQOL data from a patient after receiving a 
diagnosis of oesophageal cancer and prior to extensive cancer surgery is misleading. These 
patients often suffer from psychological distress because of their awareness of their deadly 
cancer diagnosis and they usually suffer from severe disease symptoms, e.g. dysphagia and 
weight loss. To circumvent this issue, we used normative data from a matched and 
unselected reference population. These data simulate the patients’ HRQOL, before the 
presentation of oesophageal cancer. The risk of selection bias was counteracted by the 
population-based study design with a high response rate. The fact that characteristic data 
for responders and non-responders were similar (p<0.10) also argues against selection bias. 
Information bias was counteracted by the use of well-validated questionnaires. The limited 
sample size in sub-group analyses may introduce a risk of chance influencing the results. Yet, 
all clinically relevant differences were clearly statistically significant, indicating sufficient 
precision. Oesophageal cancer is a disease that mostly affects older people. One might argue 
that deterioration in HRQOL was due to the normal ageing process or comorbidity. However, 
each patient was individually matched for age, sex and comorbidity with approximately 90 
individuals (controls) from the reference population (n=4,910) in the comparisons at both 5 
and 10 years following surgery, which should minimize any effects of age or comorbidity. 
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This is, to the best of our knowledge, the first prospective study of HRQOL up to 10 years 
after oesophageal cancer surgery. It is well established that oesophageal cancer surgery is 
associated with short-term and long-term deterioration in HRQOL.8,22,23 It is worrying that 
the poor HRQOL after oesophageal cancer surgery is persistent over a 10-year period 
following the operation. This finding might, to at least some extent, be related to the surgical 
reconstruction of the upper gastrointestinal tract required for resecting an oesophageal 
cancer. The gastric cardia with its antireflux barrier is removed and the remaining part of the 
stomach is anastomosed to the proximal oesophagus in the chest or neck, which often 
causes severe problems with reflux and regurgitation as well as insomnia due to nightly 
reflux and regurgitation.24,25 Despite the vagotomy needed to remove the oesophagus, the 
acidity of the gastric contents seem to be regained over time after surgery due to a vagal re-
innervation, which probably explains the increased problems with reflux symptoms seen 
over time. Other anatomical issues might result from the fact that most of the gastric 
reservoir is removed by the construction of a thin gastric tube, which could contribute to 
eating difficulties and loss of appetite. Scarring and fibrosis of the proximal anastomosis 
might cause dysphagia. Furthermore, the vagotomy can result in dumping and problems 
emptying the stomach. The cumulative effect of these anatomical and physiological changes 
may result in a permanent reduction in HRQOL. In older patients who are not considered fit 
for surgery, an alternative treatment might be definite chemo-radiotherapy. This organ-
sparing treatment might reduce the long-term consequences of surgery, although it does 
come with a risk of other complications and comorbidities. However, current scientific 
evidence does not support such approach in older patients considered fit enough to undergo 
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surgery because of a lower chance of long-term survival.26 Nevertheless, a thorough 
discussion about the expected life situation after surgery with patients is encouraged. 
 
In conclusion, it seems that long-term survivors of oesophageal cancer surgery experience 
reduced HRQOL in several aspects with persistent or even deterioration in specific 
symptoms. The HRQOL reduction appears to be not only related to older age, but also with 
the cancer and its treatment. Therefore, these findings call for the need for long-term 
follow-up including long-lasting rehabilitation plans for these patients.   
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Table 1. Characteristics of 92 patients surviving 10 years of oesophageal cancer surgery and 
an age-, sex-, and comorbidity-matched reference population of 4,910 people. 
Characteristics Categorization Patients Reference population 
  Number (%) Number (%) 
    
Total   92 (100) 4,910 (100) 
Sex Men 73 (79) 3,224 (66) 
Women 19 (21) 1,686 (34) 
Age at operation  
(in years) 
<40 0 (0) 0 (0) 
40-49 2 (2) 410 (8) 
50-59 6 (7) 1,073 (22)  
60-69 18 (20) 1,542 (31) 
70-79 39 (42) 1,903 (39) 
>79 27 (29) 0 (0) 
Comorbidity No 44 (48) 2,863 (58) 
Yes 48 (52) 2,047 (42) 
Tumour histology Squamous cell carcinoma 20 (22)  
Adenocarcinoma  72 (78)  
Pathological tumour 
stage 
0-I 49 (53)  
II 29 (32)  
III 13 (14)  
IV 1 (1)  
Neoadjuvant treatment No 
Yes 
87 (95) 
5 (5) 
 
Surgical approach Transthoracic 76 (83)  
Transhiatal 14 (15)  
Cervical 2 (2)  
Complications within 30 
days of surgery 
No  61 (66)  
Yes 31 (34)  
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Table 2. Health-related quality of life (HRQOL) 5 and 10 years after oesophageal cancer surgery for patients who survived at least 10 years 
(n=92), compared to an age-, sex-, and comorbidity-matched reference population (n=4,867). 
 
HRQOL aspect 
 
Mean scores (95% Confidence Intervals) 
  
Mean differences (95% Confidence Intervals) 
 
   
5 years after surgery 10 years after surgery Reference population  5-10 years p-value1 
10 years to reference 
population 
p- value2 
        
EORTC QLQ-C30        
Global quality of life 70 (66 to 75) 66 (62 to 71) 76 (76 to 77) 4 (0 to 17) - -13 (-18 to -8)  <0.0001 
Functional scales        
   Physical 86 (82 to 89) 79 (74 to 83) 88 (87 to 88) 7 (4 to 13) - -9 (-13 to -5) - 
   Role  84 (79 to 89) 74 (67 to 80) 88 (88 to 89) 10 (5 to 23) 0.0005 -15 (-22 to -9) <0.0001 
   Emotional 84 (80 to 88) 80 (76 to 85) 86 (85 to 86) 4 (0 to 16) - -9 (-14 to -5) - 
   Cognitive 84 (80 to 88) 78 (74 to 83) 88 (88 to 89) 6 (2 to 14) - -9 (-14 to -5) - 
   Social 84 (80 to 89) 81 (76 to 86) 91 (91 to 92) 3 (-1 to 20) - -11 (-16 to -6) <0.0001 
Symptom scales        
   Fatigue 29 (24 to 35) 37 (31 to 42) 19 (19 to 20) -7 (-11 to 17) - 19 (13 to 25) <0.0001 
   Nausea/vomiting 14 (10 to 18) 18 (13 to 24) 3 (2 to 3) -5 (-10 to 20) - 16 (11 to 22) <0.0001 
   Pain 17 (12 to 21) 21 (16 to 27) 19 (18 to 20) -5 (-9 to 20) - 6 (0 to 12) - 
Symptom items        
   Dyspnoea 25 (20 to 31) 32 (26 to 39) 16 (16 to 17) -7 (-12 to 23) - 17 (10 to 24) <0.0001 
   Insomnia 27 (21 to 33) 31 (24 to 38) 17 (17 to 18) -4 (-10 to 24) - 16 (9 to 22) <0.0001 
   Appetite loss  15 (10 to 21) 25 (18 to 32) 3 (3 to 4) -10 (-16 to 24) 0.0007 22 (15 to 29) <0.0001 
   Constipation 10 (6 to 14) 12 (7 to 17) 5 (5 to 6) -1 (-6 to 17) - 6 (1 to 11) - 
   Diarrhoea 28 (22 to 34) 29 (23 to 35) 6 (5 to 6) -1 (-7 to 24) - 24 (18 to 30) <0.0001 
Financial difficulties 11 (6 to 16) 11 (6 to 16) 4 (4 to 5) -1 (-4 to 14) - 8 (3 to 13) - 
        
EORTC QLQ-OES 18        
Disease-specific symptom 
scales 
       
   Dysphagia 18 (13 to 23) 18 (13 to 24) 1 (1 to 1) 0 (-6 to 25) - 18 (12 to 23) <0.0001 
   Reflux 38 (31 to 44) 40 (24 to 45) 6 (6 to 7) -2 (-8 to 26) - 34 (28 to 40) <0.0001 
   Eating difficulties 23 (18 to 28) 29 (24 to 34) 2 (2 to 3) -6 (-11 to 19) - 27 (21 to 32) <0.0001 
   Oesophageal pain 22 (17 to 27) 19 (15 to 24) 4 (4 to 5) 3 (-1 to 17) - 16 (11 to 20) <0.0001 
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Disease-specific items        
   Trouble swallowing saliva 12 (7 to 17) 15 (10 to 21) 1 (1 to 1) -4 (-10 to 25) - 14 (9 to 20) <0.0001 
   Choking 16 (11 to 21) 20 (14 to 25) 4 (3 to 4) -3 (-10 to 26) - 17 (11 to 22) <0.0001 
   Dry mouth 23 (18 to 29) 28 (22 to 34) 11 (11 to 12) -4 (-10 to 26) - 16 (10 to 22) <0.0001 
   Coughing 22 (16 to 28) 26 (20 to 33) 13 (13 to 14) -5 (-12 to 29) - 13 (6 to 19) 0.0002 
   Speech difficulties 7 (3 to 10) 10 (6 to 15) 2 (2 to 2) -4 (-7 to 16) - 8 (3 to 13) - 
   Taste problems 13 (8 to 18) 14 (9 to 19) 2 (1 to 2) -1 (-6 to 21) - 13 (7 to 18) <0.0001 
        
 Where mean scores differed clinically relevantly by ≥10 points, paired t-test1 or linear regression2 was used to test for statistical significance.  
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Table 3. Health-related quality of life (HRQOL) changes categorized as improved, stable and deteriorated between 5 years and 10 years in 92 long-term 
oesophageal cancer survivors compared with an age-, sex-, and comorbidity-matched reference population of 4,847 randomly selected people presented as 
mean score differences (MSD) and 95% confidence intervals (CIs). 
 
  Mean scores in patients who improved, were stable and deteriorated between 5 and 10 years of 
surgery compared to the mean scores of the reference population 
 
HRQOL aspect 
Improved  Stable  Deteriorated  
Number (%) MSD (95% CI) p-value Number (%) MSD (95% CI) p-value Number (%) MSD (95% CI) p-value 
 
EORTC QLQ-C30 
         
Global quality of life 21 (23) 4 (-5 to 12) - 47 (51) -13 (-20 to -7) <0.0001 24 (26) -27 (-35 to -18) <0.0001 
Functional scales          
   Physical 28 (30) 9 (5 to 14) - 33 (36) -14 (-20 to -8) <0.0001 31 (34) -21 (-28 to -13) <0.0001 
   Role 47 (51) 8 (5 to 12) - 9 (10) -36 (-57 to -15) 0.0044 35 (38) -42 (-51 to -32) <0.0001 
   Emotional 40 (43) 5 (0 to 10) - 26 (28) -17 (-26 to -9) 0.0004 26 (28) -23 (-29 to -17) <0.0001 
   Cognitive 36 (39) 7 (3 to 12) - 21 (23) -15 (-22 to -8) 0.0003 35 (38) -23 (-30 to -16) <0.0001 
   Social 53 (58) 3 (-1 to 7) - 10 (11) -34 (-50 to -18) 0.0009 28 (30) -30 (-38 to -22) <0.0001 
Symptom scales          
   Fatigue 24 (26) 0 (-10 to 10) - 25 (27) 12 (5 to 20) 0.0026 43 (47) 33 (25 to 42) <0.0001 
   Nausea/vomiting 56 (61) 2 (-1 to 5) - 10 (11) 24 (11 to 37) 0.0022 26 (28) 44 (34 to 54) <0.0001 
   Pain 51 (55) -9 (-15 to -4) - 14 (15) 11 (-1 to 22) 0.0703 27 (29) 32 (21 to 43) <0.0001 
Symptom items          
   Dyspnoea 39 (42) -10 (-16 to -5) 0.0005 22 (24) 24 (19 to 29) <0.0001 31 (34) 45 (33 to 57) <0.0001 
   Insomnia 43 (47) -11 (-15 to -8) <0.0001 26 (28) 27 (20 to 33) <0.0001 23 (25) 53 (41 to 65) <0.0001 
   Appetite loss 53 (58) -2 (-3 to -2) - 10 (11) 33 (25 to 41) <0.0001 29 (32) 62 (49 to 75) <0.0001 
   Constipation 71 (77) -5 (-6 to -5) - 7 (8) 42 (24 to 60) 0.0013 14 (15) 46 (32 to 60) <0.0001 
   Diarrhoea 46 (50) 3 (-2 to 7) - 20 (22) 37 (29 to 44) <0.0001 25 (27) 53 (42 to 65) <0.0001 
Financial difficulties 74 (80) -1 (-3 to 1) - 6 (7) 37 (24 to 50) 0.0007 11 (12) 56 (37 to 75) <0.0001 
          
EORTC QLQ-OES 18          
Disease-specific symptom 
scales 
         
   Dysphagia 52 (57) 4 (1 to 8) - 14 (15) 29 (20 to 39) <0.0001 25 (27) 39 (26 to 52) <0.0001 
   Reflux 33 (36) 17 (8 to 26) 0.0007 22 (24) 39 (30 to 48) <0.0001 36 (39) 46 (36 to 55) <0.0001 
   Eating difficulties 26 (28) 9 (2 to 16) - 34 (37) 21 (15 to 28) <0.0001 32 (35) 47 (38 to 55) <0.0001 
   Oesophageal pain 56 (61) 6 (2 to 11) - 10 (11) 13 (5 to 20) 0.0039 26 (28) 37 (28 to 46) <0.0001 
Disease-specific items          
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   Trouble swallowing saliva 67 (73) 2 (-1 to 4) - 9 (10) 32 (31 to 33) <0.0001 15 (16) 61 (46 to 76) <0.0001 
   Choking 50 (54) -2 (-4 to -1) - 20 (22) 35 (30 to 41) <0.0001 19 (18) 48 (35 to 60) <0.0001 
   Dry mouth 42 (46) -8 (-12 to -4) - 24 (26) 27 (20 to 33) <0.0001 26 (28) 46 (35 to 56) <0.0001 
   Coughing 50 (54) -8 (-13 to -4) - 13 (14) 28 (18 to 37) <0.0001 27 (29) 45 (35 to 56) <0.0001 
   Speech difficulties 73 (79) -2 (-3 to -1) - 6 (7) 37 (23 to 52) 0.001 13 (14) 49 (34 to 64) <0.0001 
   Taste problems 67 (73) 0 (-2 to 1) - 9 (10) 39 (28 to 51) <0.0001 15 (16) 54 (41 to 69) <0.0001 
          
Improved mean scores were defined by an increase over time of ≥10 mean scores in global quality of life and function scales, or a reduction of ≥10 mean 
scores in symptoms. Deteriorated mean scores were defined as a reduction of ≥10 mean scores over time in global quality or function scales, or an increase 
of ≥10 mean scores in a symptom severity scale. Stable mean scores were defined as less change than 10 means scores over time. Where mean scores 
differed clinically relevantly by ≥10 points paired t-test was used to test for statistical significance. P <0.01 was considered statistically significant. 
 
 
